Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218699 | 0.93 | MEN1 (0.49) | MEN1KMT2AKDM4EMDM2POLB | |
| SCHEMBL3910170 | 0.84 | LMNA (0.57) | MEN1KMT2ALMNAMAPT | |
| SCHEMBL6663539 | 0.82 | — | — | |
| SCHEMBL14107769 | 0.82 | CHRNA7 (0.46) | KDM4ECHRNA7MAPTPOLBALDH1A1 | |
| SCHEMBL10498542 | 0.82 | LMNA (0.70) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL9286378 | 0.81 | LMNA (0.59) | LMNAMAPT | |
| SCHEMBL8525435 | 0.80 | DHFR (0.48) | MEN1KMT2AKDM4ELMNACHRNA7 | |
| SCHEMBL27690601 | 0.80 | MEN1 (0.47) | MEN1KMT2AKDM4EMDM2LMNA | |
| SCHEMBL7432164 | 0.79 | MEN1 (0.54) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL3910163 | 0.79 | MEN1 (0.50) | MEN1KMT2AKDM4EMDM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2021101919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| US-20210000847-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20190218214-A1 | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof | VANDERBILT UNIVERSITY | 2019-07-18 | — | — | US | disclosed |
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2008075019-A1 | MODULATORS OF CB1 RECEPTORS | 7TM PHARMA A/S (DK) | 2008-06-26 | — | — | WO | disclosed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | MEN1 4220/4885KMT2A 2620/4885KDM4E 2891/4885 |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | MEN1 4394/4885KMT2A 3816/4885KDM4E 3361/4885 |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | MEN1 2214/4885KMT2A 4856/4885KDM4E 4672/4885 |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | MEN1 1366/4885KMT2A 4781/4885KDM4E 4460/4885 |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | MEN1 1057/4885KMT2A 1467/4885KDM4E 2957/4885 |
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM2A | MEN1 1965/4885KMT2A 6/4885KDM4E 14/4885 |
| US-20190218214-A1 | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof | BMP1, BMP4, BMP2 | MEN1 654/4885KMT2A 3318/4885KDM4E 802/4885 |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | MAP3K15, DSTYK, STK25 | MEN1 2868/4885KMT2A 790/4885KDM4E 1292/4885 |
| US-20210000847-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | MEN1 3979/4885KMT2A 4553/4885KDM4E 4323/4885 |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | IKZF2, RPL6, HNRNPR | MEN1 1057/4885KMT2A 1467/4885KDM4E 2957/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | MEN1 2274/4885KMT2A 4868/4885KDM4E 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.